A Study of Gimistotug (BGB-A445) in Combination With Other Investigational Agents in Participants With Non-Small Cell Lung Cancer

Overall response rate (ORR) is defined as the percentage of participants with best overall response (BOR) of a confirmed complete response (CR) or partial response (PR) as assessed by the investigators per Response Evaluation Criteria in Solid Tumors (RECIST) Version (v)1.1. CR is defined as: * Disappearance of all target lesions. Any pathological lymph nodes must have reduction in short axis to \< 10 mm. * Disappearance of all nontarget lesions and normalization of tumor marker level. All lymph nodes must be nonpathological in size (\< 10 mm short axis). * No new lesions. PR is defined as: * At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. * Non-progressive disease with regard to non-target lesions, persistence of 1 or more nontarget lesion(s) and/or maintenance of tumor marker level above the normal limits. * No new lesions.

Time frame: Response was assessed every 6 weeks for the first 9 months and every 12 weeks thereafter; maximum time on follow-up was up to 13.5 months

Population: The Intent-to-Treat population included all participants who were enrolled or randomized to a treatment cohort.

CBR is defined as the percentage of participants with BOR of a CR, PR, or stable disease lasting ≥ 24 weeks.

Time frame: Assessed from first dose to the end of the study. Response was assessed every 6 weeks for the first 9 months and every 12 weeks thereafter; maximum time on follow-up was up to 13.5 months

Population: The Intent-to-Treat Analysis Set included all participants who were enrolled or randomized to a treatment cohort.

DCR is defined as the percentage of participants with BOR of a CR, PR, or stable disease. Stable disease is defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease, with no new lesions.

Time frame: From first dose to the end of study; maximum time on follow-up was up to 13.5 months

Population: The Intent-to-Treat Analysis Set included all participants who were enrolled or randomized to a treatment cohort.

DOR is defined as the time from the first determination of an objective response as assessed by the investigator per RECIST v1 until the first documentation of progression or death, whichever comes first. Median DOR was estimated using the Kaplan-Meier method.

Time frame: From first dose to the end of study; maximum time on follow-up was up to 13.5 months.

Population: The Intent-to-Treat Analysis Set included all participants who were enrolled or randomized to a treatment cohort. Only responders were included in the analysis. No participants had a confirmed CR or PR.

Time frame: Up to 30 days following last dose. Maximum time on treatment was 11.2 months.

Population: The Anti-Drug Antibody Analysis Set included all participants who received the study drug and in whom both baseline anti-drug antibody and at least one postbaseline anti-drug antibody results are available.

An adverse event is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study drug, whether considered related to study drug or not. An SAE is any untoward medical occurrence that, at any dose, meet any of the following criteria: * Results in death * Is life-threatening * Requires hospitalization or prolongation of existing hospitalization * Results in disability/incapacity * Is a congenital anomaly/birth defect * Is considered a significant medical AE by the investigator or the sponsor based on medical judgement

Time frame: From first dose of study drug to 30 days after last dose. Maximum time on treatment was 11.2 months

Population: The Safety Analysis Set included all participants who were enrolled or randomized and received any dose of any study drug.

Time frame: Cycle 1 Day 1 2 hours and 4-6 hours post-dose, Cycle 1 Day 8 pre-dose, Cycle 1 Day 15 pre-dose, Cycle 2 Day 1 pre-dose and 2 hours and 4-6 hours post-dose, Cycle 3 Day 1 pre-dose

Population: The Pharmacokinetic Analysis Set included all participants who received any dose of study drug and for whom the valid pharmacokinetic parameters can be estimated.

Time frame: Cycle 1 Day 1 0.5 hours post-dose, Cycle 2 Day 1 predose, Cycle 5 Day 1 pre- and 0.5 hours post-dose, Cycle 9 Day 1 Predose, End of Treatment visit (30 days after last dose)

Population: The Pharmacokinetic Analysis Set included all participants who received any dose of study drug and for whom the valid study drug pharmacokinetic parameters could be estimated. Results included participants with data available at each time point.